96 results
424B1
AXDX
Accelerate Diagnostics Inc
22 Jan 24
Prospectus with pricing info
9:59pm
, as well as our assessment of the future investments needed to expand our commercial organization and support research and development activities … . If the FDA were to disagree with our regulatory assessment and conclude that approval, clearance, or de novo classification is necessary to market
S-1/A
AXDX
Accelerate Diagnostics Inc
16 Jan 24
IPO registration (amended)
7:18am
, the Accelerate Arc system, as well as our assessment of the future investments needed to expand our commercial organization and support research … could harm our business. If the FDA were to disagree with our regulatory assessment and conclude that approval, clearance, or de novo classification
S-1
7sfbq7v1m6
13 Dec 23
IPO registration
5:30pm
8-K
EX-4.1
hewcodh10u oywym
13 Jun 23
Entry into a Material Definitive Agreement
9:06am
8-K
EX-99.1
5scsc9 thlnsn9
13 Jun 23
Entry into a Material Definitive Agreement
9:06am
SD
EX-1.01
9fran
31 May 23
Conflict minerals disclosure
4:10pm
8-K
EX-99.2
j6vfnkrb0z862phnk
15 Nov 22
Accelerate Diagnostics Reports Third Quarter 2022 Financial Results
4:49pm
SD
EX-1.01
3kk5b i3i854c6z
27 May 22
Conflict minerals disclosure
4:10pm